#Stage I to III survival parameters
PSA_gamma_survival1<-c(-6,-3)
PSA_gamma_survival2<-c(-5,-1)
PSA_gamma_survival3<-c(-3,-0.01)

#Metastatic survival parameters
PSA_meta_survival1<-c(-2.5,-0.5)
PSA_meta_survival2<-c(-2,-0.3)
PSA_meta_survival3<-c(-1.5,-0.1)

#Draw Mammography with sensitivity conditional on tumour diameter parameters W-F
PSA_beta1<-c(1.47,0.1)
PSA_beta2<-c(6.51,0.5)

#Sensitivity by VDG group
PSA_Sen_VDG1<-c(96,16)
PSA_Sen_VDG2<-c(298,86)
PSA_Sen_VDG3<-c(212,93)
PSA_Sen_VDG4<-c(61,39)
Sen_VDG_av<- 0.757

#Draw supplemental Screening CDRs
PSA_MRI_cdr<-c(99.495,19799.5)
PSA_US_cdr<-c(35.89,11927)

#Draw tumour growth rate parameters
PSA_log_norm_mean <- c(0.8,1.2)
PSA_log_norm_sd <- c(1.31,0.11)

# Chemoprevention Drug parameters

# First bring in log hazard ratios from networked analysis
loghaz_ests <- readRDS("Data/PreventionOutputs.RDS")
efficacy_ests <- loghaz_ests[1]
dropout_ests <- loghaz_ests[4]

# Extract parameters for multivariate normal draws
efficacy_mu <- efficacy_ests$AnyBC$means %>% as.numeric()
efficacy_sigma <- efficacy_ests$AnyBC$vcov %>% as.matrix()
dropout_mu <- dropout_ests$Adherence$means %>% as.numeric()
dropout_sigma <- dropout_ests$Adherence$vcov %>% as.matrix()

#Drug uptake parameters
PSA_uptake_1<-c(.71, .1)
PSA_uptake_2<-c(.71, .1)

#Draw costs
PSA_cost_strat<-c(2.13387381,0.06349671)
cost_inflator<-0.1
cost_dist_sd<-(cost_inflator/1.96)^2
PSA_costvar<-c(0,cost_dist_sd)
PSA_costscreen<-c(0,cost_dist_sd)
PSA_cost_follow_up<-c(0,cost_dist_sd)
PSA_cost_biop<-c(0,cost_dist_sd)
PSA_cost_US<-c(0,cost_dist_sd)
PSA_cost_MRI<-c(0,cost_dist_sd)
PSA_cost_drug<-c(0,cost_dist_sd)

#Generate utility draws
PSA_util_1<-c(0.6,0.9)
PSA_util_4<-c(0.5,0.8)